| Objective: To observe the effects of different risk factors on the appearance of CD62 p in patients’ serum with acute cerebral infarction,and to compare the effects of indobufen and aspirin on the reveal of CD62 p in acute cerebral infarction residents,so as to provide a new methodological of antiplatelet therapy for the treatment and secondary prevention of acute cerebral infarction.Method: Rooted on the principle of randomized double-blind grouping,113 patients with acute cerebral infarction who were hospitalized in the first hospital of Jilin university department of neurology from October 2019 to December 2020,aspirin group(53 cases)and indobufen group(60 cases),evaluating the safety and effectiveness of two groups of drugs in patients with acute cerebral infarction.At the meantime,we selected the outpatient medical patients for the same period as the normal control group(60 cases).The ELISA method was used to determine the effects of different risk factors(such as hypertension,diabetes,etc.)on the expression of CD62 p,the expression and dynamic change process of CD62 p in ACI patients before and after treatment,and the effects of different antiplatelet drugs on the expression of CD62 P were investigation.Result: 1.After completing 90 days of treatment,the NIHSS scores of aspirin group and indobufen group were lowered with those than before,and the difference was statistically significant(P <0.05).However,there was no statistical difference in NIHSS scores between the two groups(before treatment and 90 d after treatment)(P= 0.862 and 0262,respectively).2.90 d m RS score comparison between the aspirin group and the indobufen group showed that the good prognosis rate of the aspirin group was 96.2%,while that of the indobufen group was 98.3%,and there was no statistical significance between the two groups(P=0.913).3.The 90 d recurrence rate in the aspirin group and the indobufen group was 15.1% and 6.7% respectively,and there was no statistical difference between the two groups(P=0.147).4.The safety index comparison between aspirin group and indobufen group showed that the incidence of aspirin adverse reactions was 7 cases(13.2%),including 4 cases of gastrointestinal symptom one case of headache and two cases of rash.The incidence of adverse effect in the indobufen group was 1.7%,with only one patient presenting headache symptoms,and there was a statistical difference in the incidence of adverse effect between the two groups(P < 0.05),indicating that the incidence of adverse effect in the indobufen group was significantly lower than that in the aspirin group.The 90 d case fatality rate did not appear.5.The expression level of CD62 p in patients with acute cerebral infarction before treatment was significantly higher than that in normal control group,with statistical significance(P < 0.05).6.Before treatment,the number of CD62 p in serum of acute cerebral infarction patients with hypertension was higher than patients without hypertension,and the difference between the two groups was statistically significant(P < 0.05).7.Before treatment,the quantity of CD62 p in patients with acute cerebral infarction and diabetes mellitus was higher than that in patients who were not diagnosed high sugar and the difference between the two groups was statistically significant(P < 0.05).8.Before treatment,the count of CD62 p in patients with acute cerebral infarction with hyperlipidemia was higher than patients without hyperlipidemia,and the difference between the two groups was statistically significant(P < 0.05).9.After drug therapy,CD62 p levels decreased in the aspirin and Indobufen groups,but there was no significant difference compared to the Indobufen group(P = 0.088> 0.05).Conclusion:1.Aspirin and indobufen are used as secondary prevention drugs for cerebral infarction,and there is no significant difference in effectiveness between the two drugs.However,in terms of safety,indobufen is safer than aspirin,and it is recommended for patients with adverse reactions to aspirin in the future.2.Both aspirin and indobufen can compel the aggressiveness of CD62 p in patients who occur acute cerebral infarction In other words,they have the effect of anti-platelet activated aggregation,but whether there is a difference between the two still needs to be further studied.3.As an indicator of platelet activation,CD62 p is significantly increased in patients with acute cerebral infarction,which shows platelet activation holds huge part in the occurrence and development of acute cerebral infarction,and hypertension,diabetes and hyperlipidemia can facilitate it.. |
PDF Full Text Request